Fischer Medical Ventures Limited

BSE: 524743 NSE: FISCHER
Fischer Medical Ventures Limited - chemicals and materials in Visakhapatnam, Andhra Pradesh, India. FY 2026 financials & compliance.
CIN L86900AP1993PLC118162 Incorporated 22 March 1993 ROC Vijayawada HQ Visakhapatnam, Andhra Pradesh, India
Active Listed - NSE: FISCHER · BSE: 524743 Public Limited Company chemicals and materials
Market Cap
₹1,768 Cr
FISCHER · NSE
Share Price
₹24.87
-1.74% today
Revenue
₹309 Cr
FY 2025-26 · +178.8% YoY
EBITDA
₹42.87 Cr
Margin 13.9%
Net Profit
₹31.03 Cr
FY 2025-26 · +1982.6% YoY
P/E (TTM)
71.7x
P/B 3.6x
Authorised capital
₹80 Cr
Registered with MCA
Paid-up capital
₹69.87 Cr
Issued & subscribed

About Fischer Medical Ventures Limited

Data last updated:

Fischer Medical Ventures Limited is a public limited company based in Visakhapatnam, Andhra Pradesh, India. It operates in the chemical distribution and retail segment of the chemicals and materials sector. It was incorporated on 22 March 1993 and has been in existence for over 33 years.

Its director Ravindran Govindan is #1,233 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Vijayawada, under CIN L86900AP1993PLC118162. Its GSTIN is 37AAACF0641D1Z7 (Andhra Pradesh). The company holds 3 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 524743 and NSE: FISCHER.

The company has an authorised share capital of ₹80 Cr and a paid-up capital of ₹69.87 Cr. It was formerly known as Fischer Chemic Limited. It is led by directors including Ravindran Govindan (Managing Director) and Svetlana Rao Raviwada (Whole-Time Director).

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Survey No. 480/2 Ap Medtech Zone Nadupura Village, Pedagantyadu Mandal Visakhapatnam, Andhra Pradesh, India – 530031.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹308.58 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹31.03 Cr (net margin 10.1%) and EBITDA of ₹42.87 Cr (EBITDA margin 13.9%). The net worth stands at ₹385.14 Cr (up 14% YoY). Total assets are valued at ₹493.21 Cr (up 16.5% YoY).

The company is associated with 1 brand: Fischer Chemic. As per MCA filings, the company has open charges of ₹40 Cr and satisfied charges of ₹20.63 Lakh on record. Court records list 2 cases involving the company, including 2 filed by the company. The company has 12 deals on record (8 market trades, 3 funding rounds, 1 acquisition), with disclosed funding of ₹81.32 Cr; the latest was in September 2026.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fischerchemic.in.

Company details

CIN L86900AP1993PLC118162
Registration Number 118162
Incorporation Date 22 March 1993
ROC Vijayawada
Listing Status Listed - Listed on NSE (FISCHER); Listed on BSE (524743)
Company Status Active
Compliance Status Active Compliant

CIN history

Fischer Medical Ventures has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L86900AP1993PLC118162, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L86900AP1993PLC118162Current
L24231TN1993PLC024661Previous
L86900MH1993PLC288371Previous
L24231MH1993PLC288371Previous
Key People
Ravindran Govindan Managing Director Svetlana Rao Raviwada Whole-Time Director Syed Jalaludin Director

Recognitions & Rankings of Fischer Medical Ventures

India's Richest People 2026 edition · 1 director · Source: Hurun India

Contact details

Fischer Medical Ventures Limited's registered office is in Visakhapatnam, Andhra Pradesh. Its website is fischerchemic.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    fischerchemic.in
  • Social Media
  • Registered Address
    Survey No. 480/2 Ap Medtech Zone Nadupura Village, Pedagantyadu Mandal Visakhapatnam, Andhra Pradesh, India – 530031
  • Industry
    Chemicals and Materials, Chemical Distribution & Retail

To see the full contact details of Fischer Medical Ventures Limited, buy the company report.

Comprehensive company report
Fischer Medical Ventures Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Fischer Medical Ventures operates one associated brand: Fischer Chemic. Each brand links to its own profile.

BrandDescriptionWebsite
Fischer Chemic
Laboratory chemicals are manufactured for research and industrial use.fischerchemic.com

Business activity

The main business activity of Fischer Medical Ventures is human health and social work activities. In detail, this covers human health activities.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
QHuman health and social work activities86Human health activities

To see the full business activity and turnover split of Fischer Medical Ventures Limited, buy the company report.

Financials of Fischer Medical Ventures Limited

FY 2025-26 filings available

Fischer Medical Ventures Limited reported revenue of ₹308.58 Cr (up 178.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹309 Cr
+178.8% YoY
EBITDA
₹42.87 Cr
+1399.0% YoY
Profit After Tax
₹31.03 Cr
+1982.6% YoY
Net Worth
₹385 Cr
+14.0% YoY
Total Assets
₹493 Cr
+16.5% YoY
Total Debt
₹107 Cr
+25.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue30911120.980.18
Revenue growth+178.8%+427.7%--
EBITDA42.872.861.850.02
EBITDA margin+13.9%+2.6%+8.8%+11.1%
Profit before tax46.372.232.100.00
Net profit31.031.491.37(0.04)
Net profit margin+10.1%+1.4%+6.5%-22.2%
EPS (₹)0.440.230.26(2.12)
Balance sheet
Total assets49342382.790.31
Net worth38533881.11(0.27)
Total debt10785.371.680.57
Cash & bank25.0525137.950.04
Net working capital24033267.000.21
Cash flow
Cash from operations(101)(86.25)(7.35)-
Cash from investing(5.22)(125)(28.79)-
Cash from financing14.1131537.06-
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue81.9297.5410186.3123.4449.1711.7539.66
Revenue growth (YoY)+249.5%+98.4%+760.4%+117.6%+131.6%---
Other income1.480.771.092.487.470.150.380.22
EBITDA11.25(3.76)21.5716.223.992.500.370.33
EBITDA margin+13.7%-3.9%+21.3%+18.8%+17.0%+5.1%+3.1%+0.8%
Depreciation1.360.930.770.510.770.510.560.29
Interest3.543.660.640.920.660.230.070.05
Profit before tax7.83(7.58)21.2517.2710.031.910.120.21
Tax4.044.861.953.365.170.500.42(0.08)
Net profit3.79(12.44)19.3013.914.861.41(0.30)0.29
EPS (₹)0.05(0.18)0.290.210.07(0.05)(0.05)0.05
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue17.395.2211.530.180.000.170.18
Revenue growth+233.1%-54.7%+6305.6%--100.0%-5.6%-
EBITDA(8.67)(2.24)(0.19)0.02(0.19)(0.01)(0.03)
EBITDA margin-49.9%-42.9%-1.7%+11.1%--5.9%-16.7%
Profit before tax(10.51)0.960.540.00(0.20)(0.03)(0.05)
Net profit(10.43)0.670.40(0.04)(0.24)0.15(0.05)
Net profit margin-60.0%+12.8%+3.5%-22.2%-+88.2%-27.8%
EPS (₹)(0.15)0.100.08(2.12)(13.52)8.17(2.39)
Balance sheet
Total assets38435879.680.310.160.240.08
Net worth33833679.68(0.27)(0.23)0.00(0.14)
Total debt45.6522.080.000.570.390.230.22
Cash & bank1.140.290.000.040.020.040.10
Net working capital24.8126.8138.380.210.020.050.07
Cash flow
Cash from operations(2.91)(22.81)0.08(0.15)(0.18)(0.06)0.01
Cash from investing(13.27)(232)(37.78)0.000.000.000.00
Cash from financing17.0225537.670.170.150.000.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.724.111.327.434.545.220.000.00
Revenue growth (YoY)-84.1%-21.3%------
Other income0.890.430.861.430.800.650.870.82
Total expenses2.6013.012.636.284.176.780.220.36
EBITDA(1.88)(8.90)(1.31)1.150.37(1.56)(0.22)(0.36)
EBITDA margin-261.1%-216.5%-99.2%+15.5%+8.1%-29.9%--
Depreciation0.770.430.080.080.080.100.030.00
Interest1.471.270.961.121.310.120.000.00
Profit before tax(3.23)(10.17)(1.49)1.38(0.22)(1.13)0.620.46
Tax0.27(1.19)0.170.540.39(0.24)0.42(0.05)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 15 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue81.9297.5410186.3123.4449.1711.7539.66
Revenue growth (YoY)+249.5%+98.4%+760.4%+117.6%+131.6%---
Other income1.480.771.092.487.470.150.380.22
EBITDA11.25(3.76)21.5716.223.992.500.370.33
EBITDA margin+13.7%-3.9%+21.3%+18.8%+17.0%+5.1%+3.1%+0.8%
Depreciation1.360.930.770.510.770.510.560.29
Interest3.543.660.640.920.660.230.070.05
Profit before tax7.83(7.58)21.2517.2710.031.910.120.21
Tax4.044.861.953.365.170.500.42(0.08)
Net profit3.79(12.44)19.3013.914.861.41(0.30)0.29
EPS (₹)0.05(0.18)0.290.210.07(0.05)(0.05)0.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue30911120.980.18
Revenue growth+178.8%+427.7%--
Other income12.311.490.500.00
Total expenses26610819.130.16
Employee cost0.002.480.380.05
EBITDA42.872.861.850.02
EBITDA margin+13.9%+2.6%+8.8%+11.1%
Depreciation2.981.630.180.00
Interest5.830.490.070.02
Profit before tax46.372.232.100.00
Tax15.341.010.270.04
Net profit31.031.491.37(0.04)
Net profit margin+10.1%+1.4%+6.5%-22.2%
EPS (₹)0.440.230.26(2.12)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital65.4563.8053.500.17
Reserves & surplus32027426.74(0.44)
Shareholders' funds (net worth)38533881.11(0.27)
Minority interest0.000.000.000.00
Secured loans8.790.000.000.00
Unsecured loans98.2985.371.680.57
Total debt10785.371.680.57
Total liabilities49342382.790.31
Assets
Gross block37.5226.7215.930.00
Net block31.6823.8814.710.00
Capital work in progress2.931.110.000.00
Investments1186.951.210.00
Inventories12.669.164.480.00
Sundry debtors28976.0722.870.17
Cash & bank balances25.0525137.950.04
Loans & advances91.0828.705.110.04
Total current assets41836570.410.25
Total current liabilities17833.683.410.04
Net working capital24033267.000.21
Total assets49342382.790.31
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash1040.950.04-
Net cash from operating activities(101)(86.25)(7.35)-
Net cash from investing activities(5.22)(125)(28.79)-
Net cash from financing activities14.1131537.06-
Net change in cash(92.37)1030.91-
Closing cash25.0525137.95-
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+178.8%+427.7%--
EBITDA growth+1399.0%+54.6%+9150.0%-
PBT growth+1979.4%+6.2%+9997.0%+9997.0%
Net income growth+1982.6%+8.8%+3525.0%-
Revenue CAGR (3Y)+1096.8%---
EBITDA CAGR (3Y)+1189.4%---
Profitability & leverage
Net income margin+10.1%+1.1%+8.7%-22.2%
Return on capital employed-+1.1%+5.3%0.0%
Return on net worth-+0.6%+4.6%0.0%
Debt / equity-0.210.030.00
Long-term debt / equity-0.040.020.00
Interest cover14.6239.844.19100.00
Efficiency & per share
Fixed asset turnover-5.192.630.00
Inventory turnover-16.239.370.00
Debtors turnover-2.241.821.06
EPS (₹)0.440.230.26(2.12)
Dividend per share (₹)0.050.050.000.00
Book value per share (₹)0.0048.1715.00(15.47)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.724.111.327.434.545.220.000.00
Revenue growth (YoY)-84.1%-21.3%------
Other income0.890.430.861.430.800.650.870.82
Total expenses2.6013.012.636.284.176.780.220.36
EBITDA(1.88)(8.90)(1.31)1.150.37(1.56)(0.22)(0.36)
EBITDA margin-261.1%-216.5%-99.2%+15.5%+8.1%-29.9%--
Depreciation0.770.430.080.080.080.100.030.00
Interest1.471.270.961.121.310.120.000.00
Profit before tax(3.23)(10.17)(1.49)1.38(0.22)(1.13)0.620.46
Tax0.27(1.19)0.170.540.39(0.24)0.42(0.05)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue17.395.2211.530.180.000.170.18
Revenue growth+233.1%-54.7%+6305.6%--100.0%-5.6%-
Other income3.493.460.750.000.000.000.00
Total expenses26.067.4611.720.160.190.180.21
Employee cost0.000.130.060.050.080.080.09
EBITDA(8.67)(2.24)(0.19)0.02(0.19)(0.01)(0.03)
EBITDA margin-49.9%-42.9%-1.7%+11.1%--5.9%-16.7%
Depreciation0.680.130.000.000.000.000.00
Interest4.650.130.020.020.010.020.02
Profit before tax(10.51)0.960.540.00(0.20)(0.03)(0.05)
Tax(0.08)0.290.140.040.04(0.18)0.00
Net profit(10.43)0.670.40(0.04)(0.24)0.15(0.05)
Net profit margin-60.0%+12.8%+3.5%-22.2%-+88.2%-27.8%
EPS (₹)(0.15)0.100.08(2.12)(13.52)8.17(2.39)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital65.4563.8053.500.170.170.170.17
Reserves & surplus24724225.31(0.44)(0.40)(0.17)(0.31)
Shareholders' funds (net worth)33833679.68(0.27)(0.23)0.00(0.14)
Secured loans0.000.000.000.000.000.000.00
Unsecured loans45.6522.080.000.570.390.230.22
Total debt45.6522.080.000.570.390.230.22
Total liabilities38435879.680.310.160.240.08
Assets
Gross block12.070.780.010.000.000.000.00
Net block11.370.680.010.000.000.000.00
Capital work in progress0.000.000.000.000.000.000.00
Investments30429141.280.000.000.000.00
Inventories0.420.070.000.000.000.000.00
Sundry debtors20.7117.0812.700.170.000.000.00
Cash & bank balances1.140.290.000.040.020.040.10
Loans & advances7.3110.1137.830.040.030.030.03
Total current assets29.5827.5550.530.250.050.070.13
Total current liabilities4.770.7412.150.040.030.020.06
Net working capital24.8126.8138.380.210.020.050.07
Total assets38435879.680.310.160.240.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.290.000.040.020.040.100.09
Net cash from operating activities(2.91)(22.81)0.08(0.15)(0.18)(0.06)0.01
Net cash from investing activities(13.27)(232)(37.78)0.000.000.000.00
Net cash from financing activities17.0225537.670.170.150.000.00
Net change in cash0.850.28(0.03)0.02(0.03)(0.06)0.01
Closing cash1.140.290.000.040.020.040.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+233.1%-54.7%+6305.6%--100.0%-5.6%-
EBITDA growth-287.1%-1079.0%-1050.0%+110.5%-1800.0%+66.7%-
PBT growth-+77.8%+9997.0%+9997.0%-566.7%+40.0%-
Net income growth-1656.7%+67.5%+1100.0%+83.3%-260.0%+400.0%-
Revenue CAGR (3Y)+358.9%-+307.8%0.0%---
EBITDA CAGR (3Y)-+127.6%+166.8%-+1.8%-63.2%-38.7%
Profitability & leverage
Net income margin-60.0%+12.8%+3.5%-22.2%-+88.2%-27.8%
Return on capital employed-+0.5%+1.4%0.0%0.0%-6.4%0.0%
Return on net worth-+0.3%+1.0%0.0%0.0%+155.6%0.0%
Debt / equity-0.050.010.000.000.000.00
Long-term debt / equity-0.040.000.000.000.000.00
Interest cover-49.73-5.49-10.53100.00-5.26-200.00-66.67
Efficiency & per share
Fixed asset turnover-13.052,306.000.000.000.000.00
Inventory turnover-149.140.000.000.000.000.00
Debtors turnover-0.351.792.120.000.000.00
EPS (₹)(0.15)0.100.08(2.12)(13.52)8.17(2.39)
Dividend per share (₹)0.050.050.000.000.000.000.00
Book value per share (₹)0.0047.8814.73(15.47)(13.34)0.18(7.99)

To see the full year-wise statements and ratios of Fischer Medical Ventures Limited, buy the company report.

Board of directors of Fischer Medical Ventures Limited

Fischer Medical Ventures has 7 current directors and 28 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Syed JalaludinDirector30 Nov 20250 Years 11 MonthsCurrent
Chan Sing En
Also directs: Time Medical International Ventures (India) Private Limited, Flynncare Health Innovations Private Limited
Director28 Oct 20251 Years 0 MonthsCurrent
Jaya Ankur Singhania
Also directs: Avabodha Bharat Legal Advisory & Training LLP, J S Singhania and Co. LLP, Sudarshan Pharma Industries Limited and 5 more
Director26 Mar 20251 Years 7 MonthsCurrent
Khairy Jamaluddin Abu BakarDirector04 May 20242 Years 6 MonthsCurrent
Svetlana Rao Raviwada
Also directs: Nanyang Biologics (India) Private Limited, Time Medical International Ventures (India) Private Limited, Flynncare Health Innovations Private Limited and 1 more
Whole-Time Director04 May 20242 Years 6 MonthsCurrent
Ravindran Govindan
Also directs: Nanyang Biologics (India) Private Limited, Time Medical International Ventures (India) Private Limited, Flynncare Health Innovations Private Limited and 1 more
Managing Director04 May 20242 Years 6 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Auditor

Fischer Medical Ventures Limited is audited by Bilimoria Mehta & Co for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Bilimoria Mehta & CoFY 2025101490W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 62.20%, foreign institutional investors hold 5.50%, domestic institutional investors hold 1.30% and retail and other public shareholders hold 31.00%.

Promoters: 62.20%DII (Domestic Institutional): 1.30%FII (Foreign Institutional): 5.50%Retail & Others: 31.00%
Sep 2026
QUARTER
62.20% Promoters
1.30% DII (Domestic Institutional)
5.50% FII (Foreign Institutional)
31.00% Retail & Others
Promoter holding - history
Now 62.20% · Sep 2026High 62.20% · Jun 2026Low 61.80% · Dec 2025
60%61%62%63%64%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 61.80%Mar 2026: 61.80%Jun 2026: 62.20%Sep 2026: 62.20%62.20%61.80%62.20%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters62.20%62.20%61.80%61.80%
Public37.80%37.80%38.20%38.20%

Charges & borrowings

Open charges
₹40 Cr
Satisfied charges
₹20.63 Lakh
Breakdown by lending institutions
Others₹40.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
31 Mar 2026101271292Others₹15 CrOpen
28 Mar 2025101079574Others₹25 CrOpen
30 May 200590289385Sundaram Finance Limited₹20.63 LakhSatisfied

To see the full charge records of Fischer Medical Ventures Limited, buy the company report.

Total charge records: 3 View all charges

Deals & funding

Fischer Medical Ventures Limited has 12 deals on record (8 market trades, 3 funding rounds, 1 acquisition), with disclosed funding of ₹81.32 Cr; the latest was in September 2026.

Total deals
12
Market trades
8
Funding rounds
3
Acquisition
1
Disclosed funding
₹81.32 Cr

Deals on record (5 of 12)

WhenDealAmountParties
Sep 2026Market trade₹22.22 CrBuyer: Trade Solvent Private Limited, L7 Hitech Private Limited
Seller: L7 Hitech Private Limited
Dec 2023Funding round₹40.08 CrInvestors: 2 individuals
Dec 2023Funding round₹36.27 CrInvestors: Other Investors, Sanjay Jain HUF
Dec 2023Funding round₹4.98 CrInvestors: Vikasa IndiaEif I Fund, 2 individuals
Dec 2012AcquisitionUndisclosedBuyer: Nuray Chemicals Private Limited
Seller: Fischer Medical Ventures Limited

To see the full deal history of Fischer Medical Ventures Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Fischer Medical Ventures Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Fischer Medical Ventures has 3 GST registrations: 3 active.

Total GSTINs
3
Active
3
GSTINStateStatusRegistered on
37AAACF0641D1Z7Andhra PradeshActive27 Sep 2024
27AAACF0641D1Z8MaharashtraActive28 Mar 2024
33AAACF0641D1ZFTamil NaduActive27 Sep 2024

To see the full GST registrations and return filing status of Fischer Medical Ventures Limited, buy the company report.

Recent activity

Fischer Medical Ventures Limited has 36 board changes on record since 2010: 8 appointments and 28 cessations. The latest: David Yeow Kok Hee was appointed as Director on 03 Sep 2026.

Appointed
David Yeow Kok Hee was appointed as Director.
Filing
Fischer Medical Ventures Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Vijayawada.
Charges
A charge with Others amounted to Rs. 15.00 Cr with Charge ID 101271292 was registered on 31 Mar 2026.
Appointed
Syed Jalaludin was appointed as Director.
Ceased
Chan Sing En ceased to be Additional Director.
Appointed
Chan Sing En was appointed as Director.
AGM
Fischer Medical Ventures Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Ceased
Jaya Ankur Singhania ceased to be Additional Director.
Charges
A charge with Others amounted to Rs. 25.00 Cr with Charge ID 101079574 was registered on 28 Mar 2025.
Appointed
Jaya Ankur Singhania was appointed as Director.
Ceased
Deepak Vyas ceased to be Company Secretary.
Ceased
Jacob Thomas ceased to be Additional Director.

31 earlier events are in the company report.

News

Fischer Medical Ventures: Approves ₹50 Crore Investment for Three Subsidiary Rights Issues
24 Sep 2026 · Exchange Update

Frequently asked questions

Fischer Medical Ventures is an active public limited company based in Visakhapatnam, Andhra Pradesh, India. The company works in chemical distribution and retail, within the chemicals and materials industry. It was incorporated on 22 March 1993 (33+ years old) and is registered under CIN L86900AP1993PLC118162. Listed on BSE: 524743 and NSE: FISCHER.

Fischer Medical Ventures reported revenue of ₹308.58 Cr for FY 2025-26 (up 178.8% YoY) based on consolidated financials.

Fischer Medical Ventures has 7 current directors:

The latest financial statements of Fischer Medical Ventures on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Fischer Medical Ventures is 37AAACF0641D1Z7, registered in Andhra Pradesh. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 27AAACF0641D1Z8 (Maharashtra), 33AAACF0641D1ZF (Tamil Nadu).

The CIN (Corporate Identification Number) of Fischer Medical Ventures is L86900AP1993PLC118162. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Fischer Medical Ventures is a listed company as per MCA records. Its shares are listed on both BSE (code: 524743) and NSE (symbol: FISCHER).

Fischer Medical Ventures has 2 court cases on record: 2 filed by the company.

Fischer Medical Ventures was incorporated on 22 March 1993, making it 33+ years old. It is registered with the Registrar of Companies, Vijayawada.

Fischer Medical Ventures has 12 deals on record (8 market trades, 3 funding rounds, 1 acquisition), with disclosed funding of ₹81.32 Cr; the latest was in September 2026.